L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park
{"title":"三阴性和her2过表达乳腺癌治疗的挑战。","authors":"L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: \"Triple negative\" and ErbB2-overexpressing, are discussed in this review.</p>","PeriodicalId":90243,"journal":{"name":"Journal of surgery and science","volume":"1 1","pages":"3-7"},"PeriodicalIF":0.0000,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012677/pdf/nihms-576637.pdf","citationCount":"0","resultStr":"{\"title\":\"Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.\",\"authors\":\"L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: \\\"Triple negative\\\" and ErbB2-overexpressing, are discussed in this review.</p>\",\"PeriodicalId\":90243,\"journal\":{\"name\":\"Journal of surgery and science\",\"volume\":\"1 1\",\"pages\":\"3-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012677/pdf/nihms-576637.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of surgery and science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of surgery and science","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: "Triple negative" and ErbB2-overexpressing, are discussed in this review.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
